Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 28	CA/CAplus patent coverage enhanced
NEWS	3	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	5	JUL 28	STN Viewer performance improved
NEWS	6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	7	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	9	AUG 15	CAplus currency for Korean patents enhanced
NEWS	10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	12	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS	14	SEP 29	IFICLS enhanced with new super search field
NEWS	15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS	16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS	17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS	19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS	20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS	21	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:29:01 ON 17 NOV 2008

=> file registry
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 12:29:17 ON 17 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2
DICTIONARY FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10582124.str



chain nodes :
7 8 9 10 11 12 13 20 21
ring nodes :
1 2 3 4 5 6 14 15 16 17 18 19

```
chain bonds :
1-8  5-7  8-9  8-20  9-10  10-11  11-12  12-13  12-21  13-15
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  14-15  14-19  15-16  16-17  17-18  18-19
exact/norm bonds :
5-7  8-9  9-10  10-11  12-21  13-15  14-15  14-19  15-16  16-17  17-18  18-19
exact bonds :
1-8  8-20  11-12  12-13
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
 11:CLASS  12:CLASS  13:CLASS  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
 20:CLASS  21:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 fam ful
FULL SEARCH INITIATED 12:29:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       66 TO ITERATE

100.0% PROCESSED       66 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L2            0 SEA FAM FUL L1

=> s l1 sss ful
FULL SEARCH INITIATED 12:29:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      118 TO ITERATE

100.0% PROCESSED      118 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01
```

```
L3            0 SEA SSS FUL L1

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                  248.01     248.22

STN INTERNATIONAL LOGOFF AT 12:29:50 ON 17 NOV 2008


Connecting via Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:ssptacrs1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  JUL 28   CA/CAplus patent coverage enhanced
 NEWS  3  JUL 28   EPFULL enhanced with additional legal status
                   information from the epoline Register
 NEWS  4  JUL 28   IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
 NEWS  5  JUL 28   STN Viewer performance improved
 NEWS  6  AUG 01   INPADOCDB and INPAFAMDB coverage enhanced
 NEWS  7  AUG 13   CA/CAplus enhanced with printed Chemical Abstracts
                   page images from 1967-1998
 NEWS  8  AUG 15   CAOLD to be discontinued on December 31, 2008
 NEWS  9  AUG 15   CAplus currency for Korean patents enhanced
 NEWS 10  AUG 27   CAS definition of basic patents expanded to ensure
                   comprehensive access to substance and sequence
                   information
 NEWS 11  SEP 18   Support for STN Express, Versions 6.01 and earlier,
                   to be discontinued
 NEWS 12  SEP 25   CA/CAplus current-awareness alert options enhanced
                   to accommodate supplemental CAS indexing of
                   exemplified prophetic substances
 NEWS 13  SEP 26   WPIDS, WPINDEX, and WPIX coverage of Chinese and
                   and Korean patents enhanced
 NEWS 14  SEP 29   IFICLS enhanced with new super search field
 NEWS 15  SEP 29   EMBASE and EMBAL enhanced with new search and
                   display fields
 NEWS 16  SEP 30   CAS patent coverage enhanced to include exemplified
                   prophetic substances identified in new Japanese-
                   language patents
 NEWS 17  OCT 07   EPFULL enhanced with full implementation of EPC2000
 NEWS 18  OCT 07   Multiple databases enhanced for more flexible patent
                   number searching
 NEWS 19  OCT 22   Current-awareness alert (SDI) setup and editing
                   enhanced
 NEWS 20  OCT 22   WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
                   Applications
```

```
 NEWS 21  OCT 24  CHEMLIST enhanced with intermediate list of
                  pre-registered REACH substances

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:03:06 ON 17 NOV 2008

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      0.21       0.21

FILE 'REGISTRY' ENTERED AT 13:03:15 ON 17 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   16 NOV 2008  HIGHEST RN 1072892-84-2
DICTIONARY FILE UPDATES:  16 NOV 2008  HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10582124a.str
```



```
chain nodes :
7  8  9  10  11  12  19  20
ring nodes :
1  2  3  4  5  6  13  14  15  16  17  18
chain bonds :
1-7  7-8  7-19  8-9  9-10  10-11  11-12  11-20  12-14
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  13-14  13-18  14-15  15-16  16-17  17-18
exact/norm bonds :
7-8  8-9  9-10  11-20  12-14  13-14  13-18  14-15  15-16  16-17  17-18
exact bonds :
1-7  7-19  10-11  11-12
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
 11:CLASS  12:CLASS  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:CLASS
 20:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss ful
FULL SEARCH INITIATED 13:03:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 118 TO ITERATE

100.0% PROCESSED 118 ITERATIONS 31 ANSWERS
SEARCH TIME: 00.00.01

L2 31 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 13:03:35 ON 17 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 Nov 2008 VOL 149 ISS 21
FILE LAST UPDATED: 16 Nov 2008 (20081116/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l2
L3 75 L2

=> s l3 and (amyotroph? or als)
7910 AMYOTROPH?
6582 ALS
L4 8 L3 AND (AMYOTROPH? OR ALS)

=> d l4 ibib abs 1-8

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:918262 CAPLUS
DOCUMENT NUMBER: 149:258394
TITLE: Arimoclomol at dosages up to 300 Mg/day is well tolerated and safe in amyotrophic lateral sclerosis
AUTHOR(S): Cudkowicz, Merit E.; Shefner, Jeremy M.; Simpson,

Elizabeth; Grasso, Daniela; Yu, Hong; Zhang, Hui; Shui, Amy; Schoenfeld, David; Brown, Robert H.; Wieland, Scott; Barber, Jack R.

CORPORATE SOURCE: NORTHEAST ALS CONSORTIUM, Neurology Clinical Trials Unit, Massachussets General Hospital, Charlestown, MA, 02129, USA

SOURCE: Muscle & Nerve (2008), 38(1), 837-844
CODEN: MUNEDE; ISSN: 0148-639X

PUBLISHER: John Wiley & Sons, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Arimoclomol is an investigational drug for amyotrophic lateral sclerosis (ALS) that amplifies heat shock protein gene expression during cell stress. The objectives of the present study were to assess the safety, tolerability, and pharmacokinetics of arimoclomol in ALS. Eighty-four participants with ALS received arimoclomol at one of three oral doses (25, 50, or 100 mg three times daily) or placebo. The primary outcome measure was safety and tolerability. A subset of 44 participants provided serum and cerebrospinal fluid (CSF) samples for pharmacokinetic anal. Participants who completed 12 wk of treatment could enroll in a 6-mo open-label study. Arimoclomol at doses up to 300 mg/day was well tolerated and safe. Arimoclomol resulted in dose-linear pharmacol. exposures and the half-life did not change with continued treatment. Arimoclomol CSF levels increased with dose. Arimoclomol was shown to be safe, and it crosses the blood-brain barrier. Serum pharmacokinetic profiles support dosing of three times per day. An efficacy study in ALS is planned.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:411857 CAPLUS

DOCUMENT NUMBER: 148:410753

TITLE: Composition comprising hydroxyamine compound for treating diseases associated with neurodegeneration

INVENTOR(S): Barber, Jack R.

PATENT ASSIGNEE(S): Cytrx Corporation, USA

SOURCE: PCT Int. Appl., 119pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008039514	A1	20080403	WO 2007-US20853	20070926
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080227813	A1	20080918	US 2007-904534	20070926
PRIORITY APPLN. INFO.:			US 2006-847606P	P 20060926
			US 2006-852791P	P 20061018

OTHER SOURCE(S): MARPAT 148:410753

AB The present invention relates to methods for treating diseases, conditions or disorders using hydroxyamine compds., and in particular, N-[2-hydroxy-3- (1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, alone or in combination with one or more other therapeutic agents, for the treatment of conditions, disorders or diseases associated with neurodegeneration in the central nervous system. The present invention also relates to pharmaceutical compns. comprising hydroxyamine compds., an addnl. therapeutic agent and a pharmaceutically acceptable carrier and methods for treating diseases using them. Thus, capsule was prepared containing N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride 25 mg, MC cellulose 252 mg, and talc 3 mg.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:223578 CAPLUS

DOCUMENT NUMBER: 148:269430

TITLE: Methods and compositions for the treatment of neurodegenerative disorders such as Huntington's disease

INVENTOR(S): Jin, Xiaowei; Wilson, Amy Beth; Staunton, Jane; MacDonald, Douglas

PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA; Chdi, Inc.

SOURCE: PCT Int. Appl., 127pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008021210	A2	20080221	WO 2007-US17751	20070810
WO 2008021210	A3	20081030		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20080044390	A1	20080221	US 2007-891552	20070810

PRIORITY APPLN. INFO.:

US 2006-837448P	P	20060811
US 2007-898479P	P	20070131
US 2007-925777P	P	20070423
US 2007-958832P	P	20070709

AB The present invention features compns., kits, and methods for treating, preventing, and ameliorating neurodegenerative disorders, e.g., Huntington's disease (HD). Screening methods for identifying candidate compds. that treat, prevent, or ameliorate neurodegenerative disorders, e.g., HD, are provided. Thus, N-terminal fragment of Htt has been shown to form protein aggregates in the nucleus, cytoplasm and processes of neurons in human HD patients and in HD animal models, as well as in many cellular models. Because of their similarities to neurons, rat pheochromocytoma PC12 cells have provided a useful model for studying neuronal cell biol.; in addition, PC12 cells are readily transfected,

selected and cloned. In order to perform screening according to a method of the present invention, PC12 cells were obtained that stably incorporated a plasmid that inducibly expresses a toxic expanded polyglutamine (103 glutamine) form of exon 1 of Htt, fused to the marker EGFP. Using the engineered PC12/HttN90Q103 cell line, a high throughput assay to screen small mols. for their ability to prevent mutant Htt exon 1-induced cell death was developed and optimized.

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1424894 CAPLUS
DOCUMENT NUMBER: 148:492092
TITLE: Heat shock proteins and protection of the nervous system
AUTHOR(S): Brown, Ian R.
CORPORATE SOURCE: Center for the Neurobiology of Stress, University of Toronto at Scarborough, Toronto, ON, Can.
SOURCE: Annals of the New York Academy of Sciences (2007), 1113(Stress Responses in Biology and Medicine), 147-158
CODEN: ANYAA9; ISSN: 0077-8923
PUBLISHER: Blackwell Publishing, Inc.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Manipulation of the cellular stress response offers strategies to protect brain cells from damage induced by ischemia and neurodegenerative diseases. Overexpression of Hsp70 reduced ischemic injury in the mammalian brain. Investigation of the domains within Hsp70 that confers ischemic neuroprotection revealed the importance of the carboxyl-terminal domain. Arimoclomol, a coinducer of heat shock proteins, delayed progression of amyotrophic lateral sclerosis (ALS) in a mouse model in which motor neurons in the spinal cord and motor cortex degenerate. Celastrol, a promising candidate as an agent to counter neurodegenerative diseases, induced expression of a set of Hsps in differentiated neurons grown in tissue culture. Heat shock "preconditioning" protected the nervous system at the functional level of the synapse and selective overexpression of Hsp70 enhanced the level of synaptic protection. Following hyperthermia, constitutively expressed Hsc70 increased in synapse-rich areas of the brain where it assocs. with Hsp40 to form a complex that can refold denatured proteins. Stress tolerance in neurons is not solely dependent on their own Hsps but can be supplemented by Hsps from adjacent glial cells. Hence, application of exogenous Hsps at neural injury sites is an effective strategy to maintain neuronal viability.
REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:576156 CAPLUS
DOCUMENT NUMBER: 146:514797
TITLE: Use of (2-hydroxy-3-(1-piperidinyl)-propoxy)-pyridine carboximidoyl chloride for treatment of selected neurological diseases
INVENTOR(S): Karpati, Gyoergy; Molnar, Maria Judit
PATENT ASSIGNEE(S): Hung.
SOURCE: Hung. Pat. Appl., 9pp.
CODEN: HUXXCV
DOCUMENT TYPE: Patent
LANGUAGE: Hungarian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

HU 9904451	A2	20021128	HU 1999-4451	19991201
PRIORITY APPLN. INFO.:			HU 1999-4451	19991201

AB The subject of the invention is the new therapeutic application of [2-hydroxy-3-(1-piperidinyl)-propoxy] pyridine-carboxyimidoyl chloride -maleate to treat sporadic amyotrophic lateral sclerosis, Friedreich disease, mitochondrial diseases accompanied by the damage of oxidative phosphorylation (OXPHOS) and in the case of inclusion testes myositis, in the presymptomatic and symptomatic phase, to prevent the harmful effects of primary etiol. factors and to alleviate the progression and clin. symptoms of the disease. According to the invention, the pharmaceutically acceptable derivative of the [2-hydroxy-3-(1-piperidinyl)propoxy]-pyridine carboxy imidoyl-chloride-maleate is used together with a pharmaceutically acceptable adjuvant, diluter or carrier in the neurol. clin. pictures defined above.

L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2006:598700 CAPLUS
DOCUMENT NUMBER:	145:499471
TITLE:	Neuroprotective agents for clinical trials in ALS
AUTHOR(S):	Traynor, B. J.; Bruijn, L.; Conwit, R.; Beal, F.; O'Neill, G.; Fagan, S. C.; Cudkowicz, M. E.
CORPORATE SOURCE:	Neurology Clinical Trials Unit, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
SOURCE:	Neurology (2006), 67(1), 20-27 CODEN: NEURAI; ISSN: 0028-3878
PUBLISHER:	Lippincott Williams & Wilkins
DOCUMENT TYPE:	Journal; General Review
LANGUAGE:	English

AB A review. Background: Riluzole is currently the only Food and Drug Administration-approved treatment for ALS, but its effect on survival is modest. Objective: To identify potential neuroprotective agents for testing in phase III clin. trials and to outline which data need to be collected for each drug. Methods: The authors identified 113 compds. by inviting input from academic clinicians and researchers and via literature review to identify agents that have been tested in ALS animal models and in patients with ALS. The list was initially narrowed to 24 agents based on an evaluation of scientific rationale, toxicity, and efficacy in previous animal and human studies. These 24 drugs underwent more detailed pharmacol. evaluation. Results: Twenty drugs were selected as suitable for further development as treatments for patients with ALS. Talampanel and tamoxifen have completed early phase II trials and have demonstrated preliminary efficacy. Other agents (ceftriaxone, minocycline, ONO-2506, and IGF-1 polypeptide) are already in phase III trials involving large nos. of patients with ALS. Remaining agents (AEOL 10150, arimoclomol, celastrol, coenzyme Q10, copaxone, IGF-1-viral delivery, memantine, NAALADase inhibitors, nimesulide, scriptaid, sodium phenylbutyrate, thalidomide, trehalose) require addnl. preclin. animal data, human toxicity and pharmacokinetic data including CNS penetration prior to proceeding to large scale phase III human testing. Further development of riluzole analogs should be considered. Conclusions: Several potential neuroprotective compds., representing a wide range of mechanisms, are available and merit further investigation in ALS.

REFERENCE COUNT:	86 THERE ARE 86 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2005:409316 CAPLUS
DOCUMENT NUMBER:	142:441894

TITLE: Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
INVENTOR(S): Greensmith, Linda; Burnstock, Geoffrey; Urbanics, Rudolf
PATENT ASSIGNEE(S): Biorex Kutato es Fejlesztoe Rt., Hung.
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041965	A1	20050512	WO 2004-HU98	20041025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285343	A1	20050512	AU 2004-285343	20041025
CA 2544332	A1	20050512	CA 2004-2544332	20041025
EP 1696922	A1	20060906	EP 2004-791657	20041025
EP 1696922	B1	20080924		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004015625	A	20061212	BR 2004-15625	20041025
CN 1901913	A	20070124	CN 2004-80039619	20041025
JP 2007509920	T	20070419	JP 2006-537449	20041025
AT 409038	T	20081015	AT 2004-791657	20041025
MX 2006PA04814	A	20061211	MX 2006-PA4814	20060428
NO 2006002401	A	20060727	NO 2006-2401	20060526
IN 2006KN01464	A	20070504	IN 2006-KN1464	20060530
US 20080039497	A1	20080214	US 2007-582124	20070510

PRIORITY APPLN. INFO.: HU 2003-3584 A 20031030
WO 2004-HU98 W 20041025

AB The invention relates to the use of a chemical substance selected from the group consisting of N-[2-hydroxy-3-(1-piperidinyl)-propoxyl]-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixts. of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compds. in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:263763 CAPLUS
DOCUMENT NUMBER: 140:399884
TITLE: Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice
AUTHOR(S): Kieran, Dairin; Kalmar, Bernadett; Dick, James R. T.; Riddoch-Contreras, Joanna; Burnstock, Geoffrey; Greensmith, Linda
CORPORATE SOURCE: The National Hospital for Neurology and Neurosurgery, Institute of Neurology, Sobell Department of Motor

Neuroscience and Movement Disorders, The Graham Watts Laboratory, University College London, London, WC1N 3BG, UK
SOURCE: Nature Medicine (New York, NY, United States) (2004), 10(4), 402-405
CODEN: NAMEFI; ISSN: 1078-8956
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition in which motoneurons of the spinal cord and motor cortex die, resulting in progressive paralysis. This condition has no cure and results in eventual death, usually within 1-5 yr of diagnosis. Although the specific etiol. of ALS is unknown, 20% of familial cases of the disease carry mutations in the gene encoding Cu/Zn superoxide dismutase-1 (SOD1). Transgenic mice overexpressing human mutant SOD1 have a phenotype and pathol. that are very similar to that seen in human ALS patients. Here we show that treatment with arimoclomol, a coinducer of heat shock proteins (HSPs), significantly delays disease progression in mice expressing a SOD1 mutant in which glycine is substituted with alanine at position 93 (SOD1G93A). Arimoclomol-treated SOD1G93A mice show marked improvement in hind limb muscle function and motoneuron survival in the later stages of the disease, resulting in a 22% increase in lifespan. Pharmacol. activation of the heat shock response may therefore be a successful therapeutic approach to treating ALS , and possibly other neurodegenerative diseases.
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	36.64	215.21
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.40	-6.40

FILE 'REGISTRY' ENTERED AT 13:15:05 ON 17 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2
DICTIONARY FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> e arimoclomol
E1            1     ARIMIDS/BI
E2            1     ARIMOCLOM/BI
E3            1 --> ARIMOCLOMOL/BI
E4            2     ARIMOL/BI
E5            2     ARIMOSA/BI
E6            1     ARIMOTO/BI
E7          130     ARIN/BI
E8           17     ARINA/BI
E9            1     ARINAE/BI
E10           1     ARINAMINE/BI
E11           4     ARINATE/BI
E12          56     ARINE/BI

=> s e3
L5            1 ARIMOCLOMOL/BI

=> d 15

L5   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   289893-25-0  REGISTRY
ED   Entered STN:  21 Sep 2000
CN   3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-
     piperidinyl)propoxy]-, 1-oxide  (CA INDEX NAME)
OTHER NAMES:
CN   Arimoclomol
FS   STEREOSEARCH
MF   C14 H20 Cl N3 O3
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, CA, CAPLUS, CBNB, EMBASE, IMSRESEARCH, PROUSDDR,
       SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry unknown.
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

              10 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
              10 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> e brx
E1            6     BRWR1/BI
E2            1     BRWY/BI
E3           32 --> BRX/BI
E4            6     BRX1/BI
E5            2     BRX1A/BI
E6            2     BRX1B/BI
```

```
E7            6     BRXE/BI
E8            2     BRXE10/BI
E9            2     BRXE11/BI
E10           2     BRXE12/BI
E11           2     BRXE13/BI
E12           2     BRXE14/BI

=> e brx220
E1            2     BRX1A/BI
E2            2     BRX1B/BI
E3            0 --> BRX220/BI
E4            6     BRXE/BI
E5            2     BRXE10/BI
E6            2     BRXE11/BI
E7            2     BRXE12/BI
E8            2     BRXE13/BI
E9            2     BRXE14/BI
E10           2     BRXE15/BI
E11           2     BRXE16/BI
E12           3     BRXE2/BI

=> s e3
L6            0 BRX220/BI

=> e brx
E1            6     BRWR1/BI
E2            1     BRWY/BI
E3           32 --> BRX/BI
E4            6     BRX1/BI
E5            2     BRX1A/BI
E6            2     BRX1B/BI
E7            6     BRXE/BI
E8            2     BRXE10/BI
E9            2     BRXE11/BI
E10           2     BRXE12/BI
E11           2     BRXE13/BI
E12           2     BRXE14/BI

=> s e3
L7           32 BRX/BI

=> d l7 1-32

L7   ANSWER 1 OF 32  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   909311-85-9  REGISTRY
ED   Entered STN:  02 Oct 2006
CN   Glucagon-like peptide 1 [2-glycine,28-alanine,31-glycine] (human clone
     WO2006/096515-SEQID-12) fusion protein with peptide (synthetic) fusion
     protein with transferrin (human) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   20: PN: WO2006096515 SEQID: 12 claimed protein
CN   BRX 0585
CN   GLP 1Tf
FS   PROTEIN SEQUENCE
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
```

```
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               2 REFERENCES IN FILE CA (1907 TO DATE)
               2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7   ANSWER 2 OF 32  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   889930-43-2  REGISTRY
ED   Entered STN:  28 Jun 2006
CN   Protein (Arabidopsis thaliana strain ecotype-Uk-2 gene BRX (BREVIS
     RADIX)) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   GenBank ABG25053
CN   GenBank ABG25053 (Translated from: GenBank AY702649)
FS   PROTEIN SEQUENCE
MF   Unspecified
CI   MAN
SR   GenBank
LC   STN Files:   CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7   ANSWER 3 OF 32  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   889930-42-1  REGISTRY
ED   Entered STN:  28 Jun 2006
CN   DNA (Arabidopsis thaliana strain ecotype-Uk-2 gene BRX (BREVIS RADIX)
     protein cDNA) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   GenBank AY702649
FS   NUCLEIC ACID SEQUENCE
MF   Unspecified
CI   MAN
SR   GenBank
LC   STN Files:   CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7   ANSWER 4 OF 32  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   889930-41-0  REGISTRY
ED   Entered STN:  28 Jun 2006
CN   Protein (Arabidopsis thaliana strain ecotype-Uk-1 gene BRX (BREVIS
     RADIX) truncated isoform) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   GenBank ABG25052
CN   GenBank ABG25052 (Translated from: GenBank AY702648)
FS   PROTEIN SEQUENCE
MF   Unspecified
CI   MAN
SR   GenBank
LC   STN Files:   CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7   ANSWER 5 OF 32  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   889930-40-9  REGISTRY
```

ED Entered STN: 28 Jun 2006
CN DNA (Arabidopsis thaliana strain ecotype-Uk-1 gene BRX (BREVIS RADIX)
    protein truncated isoform cDNA plus 3'-flank) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank AY702648
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
              1 REFERENCES IN FILE CA (1907 TO DATE)
              1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 6 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 850069-82-8 REGISTRY
ED Entered STN: 09 May 2005
CN Propanedioic acid, (6aS,11bR)-3-(acetyloxy)-7,11b-dihydrobenz[b]indeno[1,2-
    d]pyran-6a,9,10(6H)-triyl trimethyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BRX 018
FS STEREOSEARCH
MF C30 H28 O15
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

              1 REFERENCES IN FILE CA (1907 TO DATE)
              1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 7 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 688066-21-9 REGISTRY
ED Entered STN: 01 Jun 2004
CN Protein (Arabidopsis thaliana gene BRX) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 8 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 502923-63-9 REGISTRY
ED Entered STN: 14 Apr 2003
CN Amplex BRX (9CI) (CA INDEX NAME)
ENTE An activator for pectinase mixture biopolishing agent (Color Center S.A., Spain)
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 9 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 496816-64-9 REGISTRY
ED Entered STN: 03 Mar 2003
CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, [C(Z)]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BRX 51
FS STEREOSEARCH
MF C14 H20 Cl N3 O2 . C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 496816-63-8
CMF C14 H20 Cl N3 O2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 10 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 496816-62-7 REGISTRY
ED Entered STN: 03 Mar 2003
CN 3-Pyridinecarboximidoyl chloride, N-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-, [C(Z)]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BRX 53
FS STEREOSEARCH
MF C14 H20 Cl N3 O2 . C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 496816-61-6
CMF C14 H20 Cl N3 O2

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 11 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 412507-73-4 REGISTRY
ED Entered STN: 08 May 2002
CN DNA (mouse strain C57BL/6J clone UI-M-BH3-brx-a-05-0-UI EST (expressed sequence tag)) (CA INDEX NAME)
OTHER NAMES:
CN GenBank BM933144
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 12 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 392081-00-4 REGISTRY
ED Entered STN: 13 Feb 2002
CN DNA (human clone pDR2 gene BRX cDNA) (CA INDEX NAME)
OTHER NAMES:
CN 469: PN: WO2007132883 PAGE: 41 unclaimed DNA
CN GenBank AF126008
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 13 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 388566-72-1 REGISTRY
ED Entered STN: 31 Jan 2002
CN BRX-Q (9CI) (CA INDEX NAME)
ENTE An exerimental acrylamido-based ion-exchanger for protein chromatography
(Bio-Rad Laboratories, Hercules, CA)
MF Unspecified
CI PMS, MAN
PCT Manual registration
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 14 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 344670-25-3 REGISTRY
ED Entered STN: 05 Jul 2001
CN DNA (mouse strain C57BL/6J clone UI-M-BH3-brx-b-05-0-UI EST
(expressed sequence tag)) (CA INDEX NAME)
OTHER NAMES:
CN GenBank BI133445
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 15 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 326984-24-1 REGISTRY

```
ED   Entered STN:  13 Mar 2001
CN   DNA (Rattus norvegicus strain Sprague-Dawley clone
     UI-R-CV1-brx-h-03-0-UI EST (expressed sequence tag)) (9CI)  (CA INDEX
     NAME)
OTHER NAMES:
CN   410: PN: US20050084872 TABLE: 9 claimed DNA
CN   GenBank BG373361
FS   NUCLEIC ACID SEQUENCE
MF   Unspecified
CI   MAN
SR   GenBank
LC   STN Files:   CA, CAPLUS, GENBANK, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7   ANSWER 16 OF 32  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   308063-34-5  REGISTRY *
* Use of this CAS Registry Number alone as a search term in other STN files may
  result in incomplete search results.  For additional information, enter HELP
  RN* at an online arrow prompt (=>).
ED   Entered STN:  12 Dec 2000
CN   Rubber, butadiene, of cis-1,4-configuration  (CA INDEX NAME)
OTHER NAMES:
CN   Afdene Buna CB 11
CN   Ameripol CB
CN   Ameripol CB 200
CN   Ameripol CB 220
CN   Ameripol CB 221
CN   B 27
CN   B 27 (rubber)
CN   B 37
CN   B 37 (rubber)
CN   BCP 820
CN   BR 01
CN   BR 10
CN   BR 11
CN   BR 1208
CN   BR 1220
CN   BR 1220N
CN   BR 1220SG
CN   BR 1241
CN   BR 1280
CN   BR 130B
CN   BR 133P
CN   BR 150
CN   BR 150B
CN   BR 150L
CN   BR 153A
CN   BR 18
CN   BR 230
CN   BR 31
CN   BR 360L
CN   BR 40
CN   BR 51
CN   BR 60
CN   BR 700
CN   BR 700 (rubber)
CN   BR 701
CN   BR 730
```

CN BR 9000
CN BR 9002
CN BR 9002L
CN BR 9004
CN BR 9053
CN BRX 5000
CN Bud 1207
CN Bud 1254
CN Budene 1207
CN Budene 1208
CN Budene 1254
CN Budene 1280
CN Budene 207
CN Buna CB 10
CN Nipol BRX 5000
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
MF Unspecified
CI MAN, CTS
SR CA

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 17 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 289893-26-1 REGISTRY
ED Entered STN: 21 Sep 2000
CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide, (2Z)-2-butenedioate (1:1) (salt) (9CI)
OTHER NAMES:
CN BRX 220
FS STEREOSEARCH
MF C14 H20 Cl N3 O3 . C4 H4 O4
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 289893-25-0
CMF C14 H20 Cl N3 O3

Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 18 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 222187-17-9 REGISTRY
ED Entered STN: 07 May 1999
CN DNA (human clone 11.1/2.2 gene brx protein cDNA plus flanks) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN DNA (human clone 11.1/2.2 gene brx nuclear receptor-binding auxiliary protein Brx cDNA plus flanks)
CN DNA (human clone 11.1/2.2 gene brx putative rho guanine nucleotide exchange factor cDNA plus flanks)
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 19 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 222187-15-7 REGISTRY
ED Entered STN: 07 May 1999
CN Protein (human clone 11.1/2.2 gene brx reduced) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Nuclear receptor-binding auxiliary protein Brx (human clone 11.1/2.2 gene brx reduced)
CN Putative Rho guanine nucleotide exchange factor (human clone 11.1/2.2 gene brx reduced)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 20 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 215233-82-2 REGISTRY
ED Entered STN: 08 Dec 1998
CN Benzenecarboximidamide, N-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-N'-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BRX 156

MF C20 H27 N3 O2 . Cl H
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL
CRN (774166-55-1)



● HCl

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 21 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 210170-31-3 REGISTRY
ED Entered STN: 20 Aug 1998
CN Protein Brx (human) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
3 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 22 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 203805-20-3 REGISTRY
ED Entered STN: 08 Apr 1998
CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)-
(CA INDEX NAME)
OTHER NAMES:
CN BRX 005
CN BRX 235
DR 191159-87-2
MF C14 H20 N4 O
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, CHEMCATS, PROUSDDR, SYNTHLINE, TOXCENTER,
USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 23 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 201556-27-6 REGISTRY
ED Entered STN: 19 Feb 1998
CN BRX 5 (primer) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BRX 5
ENTE A polyimide primer (Cytec)
MF Unspecified
CI PMS, MAN
PCT Manual registration
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 24 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 181858-04-8 REGISTRY
ED Entered STN: 10 Oct 1996
CN RNA (measles virus strain Brx hemagglutinin gene
fragment-complementary) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank Z80797
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 25 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 164479-36-1 REGISTRY
ED Entered STN: 07 Jul 1995
CN RNA (measles virus strain Brx nucleocapsid protein gene fragment)
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ribonucleic acid (measles virus strain Brx nucleocapsid protein gene
fragment)
OTHER NAMES:
CN GenBank X84879
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 26 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 63394-00-3 REGISTRY *
* Use of this CAS Registry Number alone as a search term in other STN files may

result in incomplete search results. For additional information, enter HELP RN* at an online arrow prompt (=>).
ED Entered STN: 16 Nov 1984
CN Rubber, butadiene (CA INDEX NAME)
OTHER NAMES:
CN 150L
CN 150L (rubber)
CN 60P
CN A 24
CN Alkadienes, rubber
CN Ameripol CB 441
CN Ameripol CB 880
CN Asadene
CN Asadene 35AS
CN Asadene 35NF
CN Asadene 55AS
CN Asadene 55NF
CN Asadene AS
CN Asadene NF 35A
CN Asadene NF 35AS
CN Asadene NF 50R
CN Asaprene 610AX
CN Asaprene 700A
CN Asaprene 720A
CN Asaprene 720AX
CN Asaprene 730AX
CN Asaprene 755A
CN Asaprene 756A
CN Asaprene 760A
CN Asaprene BR 730A
CN Austrapol 1220
CN Bayer 550
CN Bon RI 1
CN BR 02L
CN BR 02LL
CN BR 1200
CN BR 1202G
CN BR 1203
CN BR 1207
CN BR 1220L
CN BR 1220SU
CN BR 1250
CN BR 1441
CN BR 15HB
CN BR 200
CN BR 200 (rubber)
CN BR 23SH
CN BR 3505
CN BR 401
CN BR 401 (rubber)
CN BR 55F
CN BR 90
CN BR 900
CN BR 9001
CN BR 9073
CN BRX 3000
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
DR 62361-95-9, 51426-11-0, 178234-67-8
MF Unspecified
CI PMS, MAN, CTS
PCT Manual registration

LC STN Files: ADISNEWS, AGRICOLA, BIOSIS, CA, CAPLUS, CHEMCATS, CHEMLIST, CIN, CSCHEM, TOXCENTER

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 27 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 3701-40-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2,7-Naphthalenedisulfonic acid, 4-hydroxy-3-[2-[4'-[2-(2-hydroxy-1-naphthalenyl)diazenyl]-2,2'-dimethyl[1,1'-biphenyl]-4-yl]diazenyl]-, sodium salt (1:2) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,7-Naphthalenedisulfonic acid, 4-hydroxy-3-[[4'-[(2-hydroxy-1-naphthalenyl)azo]-2,2'-dimethyl[1,1'-biphenyl]-4-yl]azo]-, disodium salt (9CI)
CN C.I. Acid Red 99 (7CI)
CN C.I. Acid Red 99, disodium salt (8CI)
OTHER NAMES:
CN Acid Leather Red 2BG
CN Acid Red 99
CN Acidine Red RD
CN Airedale Red RM
CN Benzyl Fast Red 2BG
CN Best Acid Milling Red FRS
CN Brilliant Milling Red
CN C.I. 23285
CN Calcocid Milling Red RC
CN Coomassie Red R
CN Dynacid Red RS
CN Elite Fast Red BG
CN Elite Fast Red R
CN Elite Fast Red RS
CN Kayanol Red RS
CN Levanol Brilliant Red BB
CN Milling Fast Red R
CN Milling Fast Red RS
CN Milling Fast Red RX
CN Milling Red PRX
CN Multicuer Red BRX
CN Naphthalene Leather Red R
CN Optanol Red R
CN Pharmanil Red RB
CN Polar Red GBD
CN Polar Red R
CN Shikiso Acid Red RS
CN Sulfonine Red RS
CN Suminol Milling Red GRS
CN Suminol Red RS
CN Supranol Fast Red RX
CN Takaoka Acid Red RS
CN Triacid Fast Red GRS
MF C34 H26 N4 O8 S2 . 2 Na
LC STN Files: CA, CAOLD, CAPLUS, CHEMCATS, CHEMLIST, RTECS*, TOXCENTER, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (25317-42-4)



●2 Na

21 REFERENCES IN FILE CA (1907 TO DATE)
21 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 28 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 2241-61-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN Benz[b]indeno[1,2-d]pyran-3,6a,9,10(6H)-tetrol, 7,11b-dihydro-, tetraacetate, (6aS,11bR)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benz[b]indeno[1,2-d]pyran-3,6a,9,10(6H)-tetrol, 7,11b-dihydro-, tetraacetate (7CI)
CN Benz[b]indeno[2,1-d]pyran-3,6a,9,10(6H)-tetrol, 7,10b-dihydro-, tetraacetate, (6aS-cis)-
OTHER NAMES:
CN BRX 019
CN Tetraacetylbrazilin
FS STEREOSEARCH
MF C24 H22 O9
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CHEMCATS, MEDLINE, PROUSDDR, SYNTHLINE, TOXCENTER
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 29 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 1658-56-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Naphthalenesulfonic acid, 4-[2-(2-hydroxy-1-naphthalenyl)diazenyl]-, sodium salt (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Naphthalenesulfonic acid, 4-[(2-hydroxy-1-naphthalenyl)azo]-, monosodium salt (9CI)
CN C.I. Acid Red 88, monosodium salt (8CI)
OTHER NAMES:
CN 11391 Red
CN 2-Naphthol Red J
CN Acid Cardinal G
CN Acid Fast Red A
CN Acid Leather Red ROC
CN Acid Red 88
CN Acid Red A
CN Acid Red A (Chinese)
CN Acid Red AV
CN Acid Red G
CN Acid Rose AV
CN Acid Scarlet G
CN Airedale Red A
CN Amacid Fast Red A
CN Ambicid Fast Red E
CN Anadurm Red A-ROC
CN Anthrosin BRX
CN Apollo Acid Rocceline
CN Atul Acid Fast Red A
CN Azo Acid Red GS
CN Basacid Red 340
CN Benzyl Red ROC
CN Benzyl Red S
CN Brasilan Red S
CN Bucacid Fast Red A
CN C.I. 15620
CN C.I. Acid Red 88
CN Calcocid Fast Red A
CN Cavalene Red A
CN Colacid Red AV
CN Colocid Fast Red A
CN Conacid Red MM
CN Daedo Acid Roccelline NS
CN Dai-ei Roccelline
CN Derma Fur Red R 150
CN Diacid Red A
CN Dinacid Fast Red A
CN Dyacid Red J
CN Dycosacid Red A
CN Eniacid Fast Red A
CN Eriosin Roccelline
CN Eriosin Roccelline SS
CN Ext D and C Red No. 8
CN Fabracid Red S-A
CN Fast Acid Red G
CN Fast Red A
CN Fast Red A (acid dye)
CN Fast Red AE
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
DR 163442-07-7, 39309-87-0

MF C20 H14 N2 O4 S . Na
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, DETHERM*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, PIRA, PROMT, RTECS*, TOXCENTER, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (18268-54-7)



● Na

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

429 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
429 REFERENCES IN FILE CAPLUS (1907 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 30 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 1326-85-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN C.I. Sulphur Black 2 (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN C.I. 53195
CN C.I. Sulfur Black 2
CN Calcogene Black 2R-CF
CN Calcogene Black RB-CF
CN Diresul Black 2R
CN Diresul Black 3R
CN Diresul Black EV-PL
CN Eclipse Deep Black BG
CN Fenoxyl Black 2R
CN Katigen Deep Black RRND-CF
CN Kayaku Sulphur Black BRX
CN Mitsui Sulphur Black ABR
CN Mitsui Sulphur Black BBRO
CN Mitsui Sulphur Black BR
CN Mitsui Sulphur Black R

CN Mitsui Sulphur Black RC
CN Nissen Black BRX
CN Sodyesul Black MCF
CN Solfo Black 3R
CN Solfo Black R
CN Sulfanol Black 2R
CN Sulfogene Carbon 4RCF
CN Sulfogene Carbon MCF
CN Sulfogene Carbon Supra CF Grains
CN Sulfogene Carbon T
CN Sulfogene Grey HlA grai
CN Sulfur Black 2
CN Sulfur Black 2RD
CN Sulfur Black 4RD
CN Sulfur Black DR
CN Sulfur Black RND
CN Sulphol Black BSP
CN Sulphol Black BSP Paste
CN Sulphol Black No. 44
CN Sulphol Black PG
CN Sulphol Black PXR Ex. Conc
CN Sulphol Black PXR Paste
CN Sulphol Black RS Grains
CN Sulphol Liquid Black QR
CN Sulphur Black 2
CN Thionol Black R
DEF This substance is identified in the COLOUR INDEX by Colour Index Constitution Number, C.I. 53195.
MF Unspecified
CI MAN
LC STN Files: CA, CAPLUS, CHEMCATS, CHEMLIST, TOXCENTER, USPAT2, USPATFULL
Other Sources: NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
11 REFERENCES IN FILE CA (1907 TO DATE)
11 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 31 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 1064-48-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[2-(4-nitrophenyl)diazenyl]-6-(2-phenyldiazenyl)-, sodium salt (1:2) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[(4-nitrophenyl)azo]-6-(phenylazo)-, disodium salt (9CI)
CN Amido Black 10B (6CI)
OTHER NAMES:
CN Acid Black 1
CN Acid Black 10A
CN Acid Black 10B
CN Acid Black 10BA
CN Acid Black 10BN
CN Acid Black 10BX
CN Acid Black 12B
CN Acid Black 4BN
CN Acid Black 4BNU
CN Acid Black 8GB
CN Acid Black Base M
CN Acid Black BRX
CN Acid Black BX

CN Acid Black H
CN Acid Black JVS
CN Acid Blue Black
CN Acid Blue Black 10B
CN Acid Blue Black 10BX
CN Acid Blue Black B
CN Acid Blue Black BG
CN Acid Blue Black Double 600
CN Acid Blue Black Sh
CN Acid Leather Blue IGW
CN Acid Leather Dark Blue G
CN Acid Leather Fast Blue Black G
CN Acidal Black 10B
CN Acidal Black MV
CN Acidal Navy Blue 3BR
CN Aciderm Black E 10B
CN Acilan Black 10B
CN Airedale Black 2BG
CN Amacid Black 10BR
CN Amide Black 10B
CN Amido Black
CN Amido Blue Black 12B
CN Apollo Acid Blue Black 10B
CN Atul Acid Black 10BX
CN Atul Acid Black BX
CN Azanol Fast Acid Black 10B
CN Azo Dark Blue C 2B
CN Azo Dark Blue HR
CN Azo Dark Blue S
CN Azo Dark Blue SH
CN Best Acid Dark Blue B
CN Black 401
CN Blue Black 12B
CN Blue Black SX
CN Borunil Grey A 10B
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
DR 12042-02-3, 68417-62-9, 84842-81-9, 86923-11-7, 31258-44-3
MF C22 H16 N6 O9 S2 . 2 Na
CI COM
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, EMBASE, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, PROMT, RTECS*, TOXCENTER, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (3121-74-2)



●2 Na

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

925 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
926 REFERENCES IN FILE CAPLUS (1907 TO DATE)
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 32 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN
RN 147-14-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN Copper, [29H,31H-phthalocyaninato(2-)-
κN29,κN30,κN31,κN32]-, (SP-4-1)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 29H,31H-Phthalocyanine, copper complex
CN 29H,31H-Phthalocyanine, copper deriv.
OTHER NAMES:
CN (Phthalocyaninato)copper
CN α-Copper phthalocyanine
CN α-Copper phthalocyanine blue
CN α-Phthalocyanine blue
CN β-Copper phthalocyanine blue
CN β-Phthalocyanine blue
CN ε-Copper phthalocyanine
CN 127EPS
CN 405D
CN 7075M
CN 79S26C
CN 79S26C chip
CN Accosperse Cyan Blue GT
CN Acnalin Supra Blue G
CN Acramin Blue F 3G
CN Akrochem 626
CN Aqualine Blue
CN Aquis BW 3571
CN Arlocyanine Blue PS
CN Aztech Chemisperse Cyan 1541
CN B 4G-KR
CN B 702W
CN B 705H
CN B 736
CN B 8M25
CN Bahama Blue BC
CN Bahama Blue BNC
CN Bahama Blue Lake NCNF
CN Bahama Blue WD
CN Bermuda Blue
CN BFD 1121
CN BGS 1
CN BGSG-C
CN BL 1531
CN Blue 7110V
CN Blue GLA
CN Blue GLA-SD
CN Blue GLSM
CN Blue Microdis
CN Blue phthalocyanaine α-form
CN Blue pigment
CN Blue Toner GTNF
CN BRS 1
CN BRX
CN BT 4651

CN C.I. 74160
CN C.I. Pigment Blue 15
CN C.I. Pigment Blue 15:1
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
DR 807622-86-2, 819860-69-0, 819860-85-0, 878390-73-9, 924902-00-1, 12767-67-8, 10482-39-0, 11097-56-6, 11129-84-3, 177529-54-3, 177646-05-8, 158853-86-2, 172308-31-5, 172826-46-9, 53802-06-5, 57916-96-8, 57425-52-2, 55819-49-3, 59518-91-1, 59966-88-0, 64333-57-9, 95660-31-4, 95917-74-1, 96024-35-0, 104921-99-5, 51331-32-9, 115284-42-9, 60880-51-5, 60937-79-3, 61489-66-5, 61489-77-8, 61537-10-8, 109675-77-6, 109766-95-2, 66121-19-5, 37223-81-7, 69431-77-2, 78170-27-1, 78413-59-9, 85255-95-4, 85256-77-5, 92909-14-3, 90452-20-3, 34567-54-9, 39378-75-1, 39473-10-4, 53028-77-6, 175386-67-1, 184007-78-1, 209343-48-6, 211564-97-5, 211925-80-3, 213190-86-4, 244244-86-8, 345338-75-2, 392718-62-6, 681847-78-9
MF C32 H16 Cu N8
CI CCS, COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DETHERM*, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

17797 REFERENCES IN FILE CA (1907 TO DATE)
1297 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
17840 REFERENCES IN FILE CAPLUS (1907 TO DATE)
134 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	85.59	300.80
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-6.40

FILE 'CAPLUS' ENTERED AT 13:20:23 ON 17 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 Nov 2008 VOL 149 ISS 21
FILE LAST UPDATED: 16 Nov 2008 (20081116/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s (15 of 17 or arimoclomol) and (aml or sclerosis)
MISSING OPERATOR L5 OF
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s (15 or 17 or arimoclomol) and (aml or sclerosis)
10 L5

```
         19197 L7
             9 ARIMOCLOMOL
          8038 AML
           253 AMLS
          8079 AML
                 (AML OR AMLS)
         33016 SCLEROSIS
            30 SCLEROSES
         33031 SCLEROSIS
                 (SCLEROSIS OR SCLEROSES)
L8           11 (L5 OR L7 OR ARIMOCLOMOL) AND (AML OR SCLEROSIS)

=> d l8 ibib abs 1-11

L8   ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2008:1320737  CAPLUS
TITLE:                   Late stage treatment with arimoclomol delays
                         disease progression and prevents protein aggregation
                         in the SOD1G93A mouse model of ALS
AUTHOR(S):               Kalmar, Bernadett; Novoselov, Sergey; Gray, Anna;
                         Cheetham, Michael E.; Margulis, Boris; Greensmith,
                         Linda
CORPORATE SOURCE:        Institute of Neurology, University College London,
                         London, UK
SOURCE:                  Journal of Neurochemistry (2008), 107(2), 339-350
                         CODEN: JONRA9; ISSN: 0022-3042
PUBLISHER:               Wiley-Blackwell
DOCUMENT TYPE:           Journal
LANGUAGE:                English
AB   Amyotrophic lateral sclerosis (ALS) is a progressive
     neurodegenerative disorder characterized by motoneuron degeneration,
     resulting in muscle paralysis and death, typically within 1-5 years of
     diagnosis.  Although the pathogenesis of ALS remains unclear, there is
     evidence for the involvement of proteasome dysfunction and heat shock
     proteins in the disease.  We have previously shown that treatment with a
     co-inducer of the heat shock response called arimoclomol is
     effective in the SODG93A mouse model of ALS, delaying disease progression
     and extending the lifespan of SODG93A mice.  However, this previous study
     only examined the effects arimoclomol when treatment was initiated
     in pre- or early symptomatic stages of the disease.  Clearly, to be of
     benefit to the majority of ALS patients, any therapy must be effective
     after symptom onset.  In order to establish whether post-symptomatic
     treatment with arimoclomol is effective, in this study we
     carried out a systematic assessment of different treatment regimes in
     SODG93A mice.  Treatment with arimoclomol from early (75 days)
     or late (90 days) symptomatic stages significantly improved muscle
     function.  Treatment from 75 days also significantly increased the
     lifespan of SODG93A mice, although treatment from 90 days has no
     significant effect on lifespan.  The mechanism of action of
     arimoclomol involves potentiation of the heat shock response, and
     treatment with arimoclomol increased Hsp70 expression.
     Interestingly, this up-regulation in Hsp70 was accompanied by a decrease
     in the number of ubiquitinpos. aggregates in the spinal cord of treated
     SODG93A mice, suggesting that arimoclomol directly effects
     protein aggregation and degradation

L8   ANSWER 2 OF 11  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2008:918262  CAPLUS
DOCUMENT NUMBER:         149:258394
TITLE:                   Arimoclomol at dosages up to 300 Mg/day is
                         well tolerated and safe in amyotrophic lateral
                         sclerosis
```

AUTHOR(S): Cudkowicz, Merit E.; Shefner, Jeremy M.; Simpson, Elizabeth; Grasso, Daniela; Yu, Hong; Zhang, Hui; Shui, Amy; Schoenfeld, David; Brown, Robert H.; Wieland, Scott; Barber, Jack R.

CORPORATE SOURCE: NORTHEAST ALS CONSORTIUM, Neurology Clinical Trials Unit, Massachussets General Hospital, Charlestown, MA, 02129, USA

SOURCE: Muscle & Nerve (2008), 38(1), 837-844
CODEN: MUNEDE; ISSN: 0148-639X

PUBLISHER: John Wiley & Sons, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Arimoclomol is an investigational drug for amyotrophic lateral sclerosis (ALS) that amplifies heat shock protein gene expression during cell stress. The objectives of the present study were to assess the safety, tolerability, and pharmacokinetics of arimoclomol in ALS. Eighty-four participants with ALS received arimoclomol at one of three oral doses (25, 50, or 100 mg three times daily) or placebo. The primary outcome measure was safety and tolerability. A subset of 44 participants provided serum and cerebrospinal fluid (CSF) samples for pharmacokinetic anal. Participants who completed 12 wk of treatment could enroll in a 6-mo open-label study. Arimoclomol at doses up to 300 mg/day was well tolerated and safe. Arimoclomol resulted in dose-linear pharmacol. exposures and the half-life did not change with continued treatment. Arimoclomol CSF levels increased with dose. Arimoclomol was shown to be safe, and it crosses the blood-brain barrier. Serum pharmacokinetic profiles support dosing of three times per day. An efficacy study in ALS is planned.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:223578 CAPLUS

DOCUMENT NUMBER: 148:269430

TITLE: Methods and compositions for the treatment of neurodegenerative disorders such as Huntington's disease

INVENTOR(S): Jin, Xiaowei; Wilson, Amy Beth; Staunton, Jane; MacDonald, Douglas

PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA; Chdi, Inc.

SOURCE: PCT Int. Appl., 127pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008021210	A2	20080221	WO 2007-US17751	20070810
WO 2008021210	A3	20081030		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,

BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
US 20080044390 A1 20080221 US 2007-891552 20070810
PRIORITY APPLN. INFO.: US 2006-837448P P 20060811
US 2007-898479P P 20070131
US 2007-925777P P 20070423
US 2007-958832P P 20070709

AB The present invention features compns., kits, and methods for treating, preventing, and ameliorating neurodegenerative disorders, e.g., Huntington's disease (HD). Screening methods for identifying candidate compds. that treat, prevent, or ameliorate neurodegenerative disorders, e.g., HD, are provided. Thus, N-terminal fragment of Htt has been shown to form protein aggregates in the nucleus, cytoplasm and processes of neurons in human HD patients and in HD animal models, as well as in many cellular models. Because of their similarities to neurons, rat pheochromocytoma PC12 cells have provided a useful model for studying neuronal cell biol.; in addition, PC12 cells are readily transfected, selected and cloned. In order to perform screening according to a method of the present invention, PC12 cells were obtained that stably incorporated a plasmid that inducibly expresses a toxic expanded polyglutamine (103 glutamine) form of exon 1 of Htt, fused to the marker EGFP. Using the engineered PC12/HttN90Q103 cell line, a high throughput assay to screen small mols. for their ability to prevent mutant Htt exon 1-induced cell death was developed and optimized.

L8 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1424894 CAPLUS
DOCUMENT NUMBER: 148:492092
TITLE: Heat shock proteins and protection of the nervous system
AUTHOR(S): Brown, Ian R.
CORPORATE SOURCE: Center for the Neurobiology of Stress, University of Toronto at Scarborough, Toronto, ON, Can.
SOURCE: Annals of the New York Academy of Sciences (2007), 1113(Stress Responses in Biology and Medicine), 147-158
CODEN: ANYAA9; ISSN: 0077-8923
PUBLISHER: Blackwell Publishing, Inc.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Manipulation of the cellular stress response offers strategies to protect brain cells from damage induced by ischemia and neurodegenerative diseases. Overexpression of Hsp70 reduced ischemic injury in the mammalian brain. Investigation of the domains within Hsp70 that confers ischemic neuroprotection revealed the importance of the carboxyl-terminal domain. Arimoclomol, a coinducer of heat shock proteins, delayed progression of amyotrophic lateral sclerosis (ALS) in a mouse model in which motor neurons in the spinal cord and motor cortex degenerate. Celastrol, a promising candidate as an agent to counter neurodegenerative diseases, induced expression of a set of Hsps in differentiated neurons grown in tissue culture. Heat shock "preconditioning" protected the nervous system at the functional level of the synapse and selective overexpression of Hsp70 enhanced the level of synaptic protection. Following hyperthermia, constitutively expressed Hsc70 increased in synapse-rich areas of the brain where it assocs. with Hsp40 to form a complex that can refold denatured proteins. Stress tolerance in neurons is not solely dependent on their own Hsps but can be supplemented by Hsps from adjacent glial cells. Hence, application of exogenous Hsps at neural injury sites is an effective strategy to maintain neuronal viability.

REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1207486 CAPLUS
DOCUMENT NUMBER: 147:466838
TITLE: Identifying signal transduction pathways that mediate nervous system plasticity by gene expression profiling and the selection of pathway modulators for therapeutic use
INVENTOR(S): Sur, Mriganka; Tropea, Daniela; Kreiman, Gabriel
PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA
SOURCE: PCT Int. Appl., 407pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007120847	A2	20071025	WO 2007-US9172	20070412

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-792275P P 20060414

AB Methods for identifying genes and pathways involved in neuronal plasticity by anal. of the effects of deprivation and stimulation on patterns of gene expression in nervous tissue are described. The invention applies some of these methods to identify genes that are differentially regulated in at least a portion of the nervous system of an individual subjected to conditions known to result in altered nervous system plasticity, i.e., dark rearing (DR) or monocular deprivation (MD). The genes are targets for pharmacol. agents that modify plasticity and candidate agents modifying neuronal plasticity are identified. The invention also identifies biol. pathways that are enriched in the products of genes that are differentially regulated under conditions known to result in altered nervous system plasticity. The methods and compns. may be administered to a subject suffering from damage to the nervous system or from a neuropsychiatric disorder in order to enhance recovery, reorganization, or function of the nervous system. The methods optionally include administering a proteolysis-enhancing agent to the subject.

L8 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:711978 CAPLUS
DOCUMENT NUMBER: 147:377138
TITLE: Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis
AUTHOR(S): Bedlack, Richard S.; Traynor, Bryan J.; Cudkowicz, Merit E.
CORPORATE SOURCE: Duke University Medical Center, Durham, NC, USA
SOURCE: Expert Opinion on Emerging Drugs (2007), 12(2), 229-252
CODEN: EOEDA3
PUBLISHER: Informa Healthcare

DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. It has been > 130 years since the first description of the upper and lower motor neuron disease called amyotropic lateral sclerosis (ALS). Sadly, there has been little change in the long interval over which this disease is diagnosed, or in its poor prognosis. Significant gains have been made, however, in understanding its pathophysiol. and in symptomatic care. Disease-causing mutations have been identified and used to create animal models. Other identified mutations may increase susceptibility and cause disease only in a particular environment and at a particular age. A number of 'downstream' mol. pathways have been implicated, including transcriptional disturbances, protein aggregation, excitotoxicity, mitochondrial dysfunction, oxidative stress, neuroinflammation, cytoskeletal and axonal transport derangements, growth factor dysregulation and apoptosis. This knowledge has led to an impressive pipeline of candidate therapies that offer hope for finally being able to alter ALS disease progression. These are described and prioritized herein, and suggestions are offered for efficiently sifting through them.
REFERENCE COUNT: 148 THERE ARE 148 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:598700 CAPLUS
DOCUMENT NUMBER: 145:499471
TITLE: Neuroprotective agents for clinical trials in ALS
AUTHOR(S): Traynor, B. J.; Bruijn, L.; Conwit, R.; Beal, F.; O'Neill, G.; Fagan, S. C.; Cudkowicz, M. E.
CORPORATE SOURCE: Neurology Clinical Trials Unit, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
SOURCE: Neurology (2006), 67(1), 20-27
CODEN: NEURAI; ISSN: 0028-3878
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Background: Riluzole is currently the only Food and Drug Administration-approved treatment for ALS, but its effect on survival is modest. Objective: To identify potential neuroprotective agents for testing in phase III clin. trials and to outline which data need to be collected for each drug. Methods: The authors identified 113 compds. by inviting input from academic clinicians and researchers and via literature review to identify agents that have been tested in ALS animal models and in patients with ALS. The list was initially narrowed to 24 agents based on an evaluation of scientific rationale, toxicity, and efficacy in previous animal and human studies. These 24 drugs underwent more detailed pharmacol. evaluation. Results: Twenty drugs were selected as suitable for further development as treatments for patients with ALS. Talampanel and tamoxifen have completed early phase II trials and have demonstrated preliminary efficacy. Other agents (ceftriaxone, minocycline, ONO-2506, and IGF-1 polypeptide) are already in phase III trials involving large nos. of patients with ALS. Remaining agents (AEOL 10150, arimoclomol, celastrol, coenzyme Q10, copaxone, IGF-1-viral delivery, memantine, NAALADase inhibitors, nimesulide, scriptaid, sodium phenylbutyrate, thalidomide, trehalose) require addnl. preclin. animal data, human toxicity and pharmacokinetic data including CNS penetration prior to proceeding to large scale phase III human testing. Further development of riluzole analogs should be considered. Conclusions: Several potential neuroprotective compds., representing a wide range of mechanisms, are available and merit further investigation in ALS.
REFERENCE COUNT: 86 THERE ARE 86 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:409316 CAPLUS
DOCUMENT NUMBER: 142:441894
TITLE: Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
INVENTOR(S): Greensmith, Linda; Burnstock, Geoffrey; Urbanics, Rudolf
PATENT ASSIGNEE(S): Biorex Kutato es Fejlesztoe Rt., Hung.
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041965	A1	20050512	WO 2004-HU98	20041025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285343	A1	20050512	AU 2004-285343	20041025
CA 2544332	A1	20050512	CA 2004-2544332	20041025
EP 1696922	A1	20060906	EP 2004-791657	20041025
EP 1696922	B1	20080924		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004015625	A	20061212	BR 2004-15625	20041025
CN 1901913	A	20070124	CN 2004-80039619	20041025
JP 2007509920	T	20070419	JP 2006-537449	20041025
AT 409038	T	20081015	AT 2004-791657	20041025
MX 2006PA04814	A	20061211	MX 2006-PA4814	20060428
NO 2006002401	A	20060727	NO 2006-2401	20060526
IN 2006KN01464	A	20070504	IN 2006-KN1464	20060530
US 20080039497	A1	20080214	US 2007-582124	20070510
PRIORITY APPLN. INFO.:			HU 2003-3584 A	20031030
			WO 2004-HU98 W	20041025

AB The invention relates to the use of a chemical substance selected from the group consisting of N-[2-hydroxy-3-(1-piperidinyl)-propoxyl]-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixts. of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compds. in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:263763 CAPLUS
DOCUMENT NUMBER: 140:399884
TITLE: Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice

AUTHOR(S): Kieran, Dairin; Kalmar, Bernadett; Dick, James R. T.; Riddoch-Contreras, Joanna; Burnstock, Geoffrey; Greensmith, Linda

CORPORATE SOURCE: The National Hospital for Neurology and Neurosurgery, Institute of Neurology, Sobell Department of Motor Neuroscience and Movement Disorders, The Graham Watts Laboratory, University College London, London, WC1N 3BG, UK

SOURCE: Nature Medicine (New York, NY, United States) (2004), 10(4), 402-405
CODEN: NAMEFI; ISSN: 1078-8956

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition in which motoneurons of the spinal cord and motor cortex die, resulting in progressive paralysis. This condition has no cure and results in eventual death, usually within 1-5 yr of diagnosis. Although the specific etiol. of ALS is unknown, 20% of familial cases of the disease carry mutations in the gene encoding Cu/Zn superoxide dismutase-1 (SOD1). Transgenic mice overexpressing human mutant SOD1 have a phenotype and pathol. that are very similar to that seen in human ALS patients. Here we show that treatment with arimoclomol, a coinducer of heat shock proteins (HSPs), significantly delays disease progression in mice expressing a SOD1 mutant in which glycine is substituted with alanine at position 93 (SOD1G93A). Arimoclomol-treated SOD1G93A mice show marked improvement in hind limb muscle function and motoneuron survival in the later stages of the disease, resulting in a 22% increase in lifespan. Pharmacol. activation of the heat shock response may therefore be a successful therapeutic approach to treating ALS, and possibly other neurodegenerative diseases.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1971:401127 CAPLUS

DOCUMENT NUMBER: 75:1127

ORIGINAL REFERENCE NO.: 75:187a,190a

TITLE: Histochemistry of myelin. XII. Anionic staining of myelin basic proteins for histology, electrophoresis, and electron microscopy

AUTHOR(S): Adams, Colin W. M.; Bayliss, Olga B.; Hallpike, J. F.; Turner, D. R.

CORPORATE SOURCE: Med. Sch., Guy's Hosp., London, UK

SOURCE: Journal of Neurochemistry (1971), 18(3), 389-94
CODEN: JONRA9; ISSN: 0022-3042

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Phosphotungstic acid hematoxylin, trypan blue, and amido black techniques were developed as anionic dye methods for staining myelin basic proteins. All methods displayed central and peripheral nervous system myelin in histochem. prepns. and stained brain basic proteins in electrophoretic polyacrylamide gels: phosphotungstic acid hematoxylin appeared to be the most selective of these techniques. Electron photomicrographs of peripheral nerve stained by phosphotungstic acid hematoxylin showed that the major part of myelin basic protein is located in the period dense line. The basic proteins stained by phosphotungstic acid hematoxylin showed an early loss in rat sciatic nerve undergoing Wallerian degeneration and had completely disappeared from the center of 20 plaques of multiple sclerosis.

L8 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1959:73788 CAPLUS
DOCUMENT NUMBER: 53:73788
ORIGINAL REFERENCE NO.: 53:13384b
TITLE: Histochemistry and classification of the Pelizaeus-Merzbacher disease
AUTHOR(S): Seitelberger, Franz
CORPORATE SOURCE: Univ. Vienna, Munich, Germany
SOURCE: Cerebral Lipidoses (J. N. Cumings and A Lowenthal, editors. Charles C Thomas, publisher) (1957), Volume Date 1955, (Symposium, Antwerp), 92-7
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB Review with reference.

=>